دورية أكاديمية

Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma

التفاصيل البيبلوغرافية
العنوان: Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma
المؤلفون: Yunjie Duan, Yongxing Du, Yongrun Mu, Zongting Gu, Chengfeng Wang
المصدر: Frontiers in Molecular Biosciences, Vol 9 (2022)
بيانات النشر: Frontiers Media S.A., 2022.
سنة النشر: 2022
المجموعة: LCC:Biology (General)
مصطلحات موضوعية: pancreatic adenocarcinoma, SUMO family, TP53, M6A, biomarkers, prognosis, Biology (General), QH301-705.5
الوصف: Background: Pancreatic adenocarcinoma (PAAD) has a high degree of malignancy and a very poor prognosis, and the 5-year overall survival rate of patients is approximately 7%. To improve the prognosis of patients with PAAD, a more comprehensive and in-depth study of the pathogenesis of PAAD and the identification of new diagnostic markers and treatment targets are urgently needed. Increasing evidence supports that the small ubiquitin-like modifier (SUMO) family is closely related to the occurrence and development of a variety of cancers. However, the function of the SUMO family in PAAD is not clear, and related research is very scarce.Methods: R, Cytoscape, cBioPortal, and other software and online databases were used to comprehensively analyze the expression characteristics, prognostic value, and oncogenic mechanism of the SUMO family in PAAD.Results: SUMO family members are highly expressed in PAAD, and high expression of SUMO family members is significantly associated with poor clinicopathological features and poor prognosis in PAAD patients. In addition, SUMO family members are significantly coexpressed with M6A methylation regulators and various oncogenes and play an activating role in various oncogenic pathways, including EMT. Furthermore, it is worth noting that the close association between SUMO family members and TP53 mutation status and the negative regulatory effect of SUMO1/2 on PAAD immunity may represent the potential mechanism by which SUMO family members promote the development of PAAD. Moreover, the coexpression characteristics of SUMO family members and a variety of cancer-promoting immune checkpoint genes, as well as the positive correlation between SUMO4 expression level and the sensitivity of various targeted or chemotherapeutic drugs, including gemcitabine, paclitaxel, and doxorubicin, suggest future clinical directions of this study.Conclusion: The SUMO family is closely related to the occurrence and development of PAAD and can be used as a new biomarker and therapeutic target for patients with PAAD.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2296-889X
Relation: https://www.frontiersin.org/articles/10.3389/fmolb.2022.1096679/full; https://doaj.org/toc/2296-889X
DOI: 10.3389/fmolb.2022.1096679
URL الوصول: https://doaj.org/article/c9207945ee9b48a4be1ece088104f4b2
رقم الأكسشن: edsdoj.9207945ee9b48a4be1ece088104f4b2
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2296889X
DOI:10.3389/fmolb.2022.1096679